新数据揭示CD47表达水平可预测ALX Oncology Evorpacept联合Ziihera(Zanidatamab-Hrii)治疗晚期HER2阳性乳腺癌的疗效

美股速递
Jan 30

最新研究数据显示,CD47生物标志物的表达水平可作为预测晚期HER2阳性乳腺癌患者对ALX Oncology Holdings(ALXO)旗下Evorpacept与Ziihera(Zanidatamab-Hrii)联合疗法临床反应的关键指标。该发现为精准医疗提供了新的分子分型依据,有望优化治疗人群筛选策略。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10